Introduction
The functioning of the placenta as a fetomaternal organ is of paramount importance throughout pregnancy in terms of intrauterine development of the fetus. Placental development involves a series of complex structural and physiological changes, to physically connect the mammalian embryo to its mother (Cross et al., 1994) and functionally synchronize fetal development. Such events involve invasion of the constituent cells of the placenta (the trophoblasts) into the uterine wall (Pijnenborg et al., 1981) , high cell proliferation, migration and many malignancylike phenotypes that have led to the definition of the placenta as a 'pseudo-malignant' type of tissue (Strickland and Richards, 1992; Redman, 1997; Even-Ram et al., 1998; Ferretti et al., 2007) . Placental trophoblasts share several features with malignant cells in terms of their biological behavior, such as rapid proliferation and invasiveness (Bischof et al., 2001 ) and the gene expression profile, especially the expression of certain proto-oncogenes (Ohlsson, 1989; Janneau et al., 2002; Chiu et al., 2007) , activation of telomerase and the acquisition of a rich blood supply (Soundararajan and Rao, 2004) . Several oncogenes are similarly expressed by both normal trophoblasts and cancer cells, especially the oncogenes encoding transcription factors such as c-myc and human telomerase reverse transcriptase (hTERT). However, the specialized phenotypic behavior of placental trophoblasts is highly regulated, unlike most tumor tissues, involving a highly complex differential global gene expression profile varying with gestational age. The importance of this regulatory mechanism in placental development becomes clearer in the case of aberrant trophoblastic proliferation and invasion, resulting in various pregnancy-related disorders, such as gestational trophoblastic diseases (GTDs: hydatidiform mole and choriocarcinoma), which result from uncontrolled trophoblast proliferation, while inadequate trophoblast invasion has been implicated in the pathophysiology of pre-eclampsia (PE).
C-myc encodes a transcription factor containing the bHLH/LZ (basic Helix-Loop-Helix Leucine Zipper) domain and can bind to Enhancer Box sequences (E-boxes) via its bHLH domain recruiting histone acetyltransferases and further, dimerizing with its partner Max, with its leucine zipper domain, thus regulating the expression of a large number of downstream target genes (Gearhart et al., 2007) involved in cell growth and proliferation. Overexpression of c-myc resulting in the up-regulation of many other genes is known to be involved in the development of cancer. The catalytic subunit of hTERT is one such c-myc downstream target gene (Horikawa et al., 1999) . C-myc overexpression thus has a role in telomerase activation, which in turn would allow permanent proliferation. hTERT is involved in the maintenance of the telomeric length (Gomez et al., 2012) and in the cellular replicative life span (Nakamura and Cech, 1998) and is generally repressed in most adult human somatic cells, limiting their proliferative potential due to induced chromosomal instability, leading to cellular senescence after a few cell divisions. However, strong telomerase activity has been detected in human cancer cells, with unlimited replication potential (Kim et al., 1994) . hTERT also has oncogenic properties, whereby its expression transforms some cell lines by promoting tumorogenesis, inhibiting apoptosis and stimulating mitogen-independent growth (Morales et al., 1999) . Like most progressive cancers, and in contrast to the majority of human somatic tissues, the human placenta expresses telomerase activity. Studies have shown a high level of telomerase expression in early placental villi with a drastic decrease with advancing gestation (Chen et al., 2002; Nishi et al., 2004) . Further, in vitro studies using models for trophoblast differentiation have demonstrated a negative regulation of telomerase activity during placental differentiation (Rama et al., 2001) . These studies highlight the high proliferative potential of trophoblastic cells during early pregnancy (Soundararajan and Rao, 2004) .
Increased telomerase activity and c-myc expression have already been reported in the early weeks of pregnancy and in cases of GTDs, such as hydatidiform mole and choriocarcinoma (Pfeifer-Ohlsson et al., 1984; Chen et al., 2002) , suggesting that these genes may be important in the pathogenesis of a hydatidiform mole and choriocarcinoma (Fulop et al., 1998) . Further, c-myc expression has been found both in villous and extravillous cytotrophoblasts (Pfeifer-Ohlsson et al., 1984; Goustin et al., 1985; Roncalli et al., 1994) .
Although the expression of these genes varies with advancing gestation and plays a role in placental disorders, the molecular mechanisms regulating their differential expression have not been identified. Recently, studies have shown a role for DNA methylation (Rahnama et al., 2006) and histone modifications (Dokras et al., 2006) in the regulation of the differential expression of E-cadherin and maspin in placenta, respectively. Therefore, we hypothesize that epigenetic regulation of c-myc and hTERT could be the possible regulatory mechanism for their differential expression. Further, the expression of these genes has not been studied in reference to the known invasive potential of placental derived cell lines, such as HTR-8/SVneo (a highly invasive cell line derived from transformed extravillous trophoblasts) and JEG-3 cells (a comparatively less invasive cell line derived from placental choriocarcinoma) (Suman and Gupta, 2012) . Moreover, the presence of circulating fetal DNA in maternal blood has led the way to the development of fetal DNA epigenetic markers, for example RASSF1A and maspin (Chim et al., 2005; Chan et al., 2006) , that can be used for physiological pregnancies but there is no known epigenetic marker specific for pathological pregnancies.
Based on the previous literature, in this study we analyzed the mRNA expression of c-myc and hTERT in reference to the epigenetic mechanisms of DNA methylation and histone modification, in order to find the regulatory mechanisms behind their differential expression and further investigate the correlation between c-myc and hTERT mRNA expression in normal and pathological pregnancies. mRNA expression of these genes was further assessed in placental-derived cell lines with different invasive potentials. Finally, based on our DNA methylation data, we aimed to search for a fetal DNA epigenetic marker that is specific for pathological pregnancies.
Materials and Methods

Ethical approval
This study was carried out in the department of Biochemistry in collaboration with the department of Obstetrics and Gynecology at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. The protocol of the study was approved by the Institute Ethics Committee (IEC) and a written informed consent was obtained from all participants.
Subjects and sample collection
A total of 135 pregnant women attending the Department of Obstetrics and Gynaecology with the clinical diagnosis of normal pregnancy or pregnancy-related disorders (PE, hydatidiform mole) were included in this study. These pregnant women with a singleton pregnancy were classified into three normal groups and two disorder groups based on the gestational age and clinical conditions (all data here are mean + SD): the normal groups were first-trimester (6-11 weeks, who desired to undergo medical termination of pregnancy (MTP) by suction evacuation, n ¼ 30, age 27.90 + 3.44 years and gestation 8.22 + 1.44 weeks), second-trimester (16-20 weeks, who desired to undergo MTP, n ¼ 30, age 27.65 + 3.91 years and gestation 18 + 1.62 weeks) and third-trimester (37-40 weeks, n ¼ 30, age 28 + 3.5 years and gestation 38.06 + 0.877 weeks), while the disorder groups were PE (clinical symptoms of systolic pressure 140 mmHg and diastolic pressure 90 mmHg, proteinuria . 300 mg in 24 h, n ¼ 30, age 26 + 3.38 years and gestation 35.27 + 2.53 weeks) and hydatidiform mole (in first or early second trimester, diagnosed by ultrasonography and confirmed by histopathology, n ¼ 15, age 25.09 + 2.63 years and gestation 13.68 + 2.9 weeks).
Placental villi samples were collected after elective pregnancy terminations from pregnant women with normal first, second trimester and hydatidiform mole pregnancy, or after cesarean section or vaginal deliveries in case of normal third-trimester and pre-eclamptic pregnancies. A maternal peripheral blood sample (10 ml) was collected in each case just before these obstetric procedures; however, in case of a normal third-trimester pregnancy 10 ml of maternal peripheral blood was also collected 24 h after delivery and was processed similarly. Maternal blood samples were processed to separate leukocytes and plasma.
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Sample processing
Maternal blood samples were centrifuged at 1600 g for 10 min (min) at 48C and supernatant was collected and recentrifuged at 16 000 g for 10 min at 48C for harvesting cell-free plasma samples (Chiu et al., 2001) , which were stored at 2808C for isolation of cell-free circulating DNA, while the remaining peripheral blood cell portion was processed for red blood cell (RBC) lysis and isolation of maternal leukocytes using RBC lysis buffer (0.82% NH 4 Cl) and phosphate-buffered saline (PBS). Placental tissue obtained from each subject was processed in chilled PBS for the separation of clear placental villi free from fibroid tissue, blood clots, amnion and basement membrane.
Isolation of cytotrophoblasts from first-trimester villi
First-trimester cytotrophoblasts were isolated from placentas (6-11 weeks) by modifying the method of Fisher et al. (1989) . Briefly, a sample of 2 g of firsttrimester villous tissue was dissected from chorionic membranes and washed in sterile ice-cold tissue washing buffer (PBS 1×, antibiotic-antimycotic Solution 1×, Gentamycin 50 mg/ml, D-Glucose 0.1% w/v), then was subjected to the first enzymatic digestion (PBS 1×, antibiotic-antimycotic Solution 1×, Gentamycin 50 mg/ml, HEPES 15 mM, MgSO 4 5 mM, Trypsin 0.25%, DNaseI 0.02% w/v) for 10 min at 378C without shaking and then passed through a pre-equilibrated 60 mm mesh to remove the supernatant containing syncytiotrophoblasts. The rest of the tissue was collected from the mesh and subjected to further rounds of enzymatic digestion at 378C initially for 30 min and then for another two sequential rounds of 10 min each. After each step the cell suspension was passed through pre-equilibrated 60 mm mesh to remove cellular debris and collect the filtrate containing isolated cytotrophoblasts. Fetal bovine serum (FBS) was used to inactivate trypsin. The filtrates were then centrifuged, the cell pellets were resuspended in sterile PBS and subjected to enrichment on a preformed 10-70% Percoll gradient (all reagents were purchased from Sigma Chemical Co., St. Louis, MO, USA) at 800 g for 20 min at 208C. The white buffy layer (the mononuclear cells containing cytotrophoblasts) below the top layer was collected carefully by micropipette and was immunopurified to a pure population of cytotrophoblasts by the negative selection method using Quantitative Real-time PCR Total RNA was isolated from placental villi, maternal blood cells, and the JEG-3 and HTR-8/SVneo cell lines using TRIzol (Ambion, Life Technologies Corporation, CA, USA), and 1 mg was reverse-transcribed using RevertAidTM M-MuLV-RT kit (MBI Fermentas, Life Sciences, USA). The resulting cDNA was quantified using Applied Biosystems StepOnePlus TM Real-Time PCR System under the following conditions: 1 cycle of 958C for 10 min, 40 cycles of 958C for 15 s, primer-specific annealing temperature for 1 min and followed by a melt curve of 958C for 10 s, 608C for 1 min and 958C for 15 s. The PCR mixture contained 10 ml of SYBR Green master mix (Applied Biosystems, Inc., Life Technologies Corporation, CA, USA), 500 nM of each primer and 1.5 mM of MgCl 2 and 1 ml (almost 60 ng) of cDNA template. Primers were designed using the online Primer-BLAST tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and cross-checked for primer self-dimerization and potential hairpin formation using the online software Oligonucleotide Properties Calculator (http://www.basic. northwestern.edu/ BIOTOOLS/OLIGOCALC.HTML) ( Table I ). The mRNA expression levels of two housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S ribosomal RNA (18S rRNA) were analyzed initially in different groups for their stability and, as both showed no statistically significant variation between groups (data not shown), the expression of GAPDH was used as the endogenous control. The comparative Ct method (DDCT) (Livak and Schmittgen, 2001 ) was used for quantification of the transcripts. Measurement of DCt was performed in triplicate.
Methylation-sensitive high resolution melting
DNA was extracted for methylation analysis from the placental villi, the corresponding maternal blood leukocytes, cultured cytotrophoblasts, and cultured JEG-3 and HTR-8/SVneo cell lines by using the genomic DNA isolation kit (Real Genomics, Real Biotech Corporation, Taipei, Taiwan), while circulating DNA was isolated from maternal plasma using the Miniprep DNA isolation kit (Bioserve, MD, USA) according to the manufacturer's instructions. Promoter region CpG methylation analysis of the cmyc and hTERT was carried out by methylation-sensitive high resolution melting (MS-HRM), which is a real-time PCR-based technique that uses new generation saturating HRM dye that intercalates specifically to dsDNA. MS-HRM can differentiate sequences on the basis of the GC content, which determines the temperature at which the dsDNA sequence denatured (Wojdacz and Dobrovic, 2007) . A standard curve comprising 0, 0. 5, 5, 10, 20, 40, 60, 80 and 100% methylation standards was generated by mixing 0 and 100% methylated standards in different proportions, for the analysis of the percentage of methylation of unknown samples. For the 0% methylated standard, a commercial unmethylated DNA (Qiagen -EpiTect w Control DNA) was used, while the 100% methylated standard was generated by treating genomic DNA with M.SssI enzyme (CpG Methyltransferase, New England Biolabs, Beverly, MA, USA), according to the manufacturer's instructions. An aliquot of 1 mg of DNA from each sample and methylation standards was treated with sodium bisulfite using the EZ DNA Methylation-Gold Kit (Zymo Research, USA), according to the manufacturer's instructions. Sodium bisulfite treatment converts all unmethylated cytosines into uracil, leaving methylated cytosines unchanged and thus creating single nucleotide base differences in the amplicons. Primers were designed for the promoter region of c-myc and hTERT on the basis of parameters set earlier (Wojdacz et al., 2008) to amplify an 80 bp sequence containing 9 CpG for c-myc, and 139 bp sequence containing 19 CpG for hTERT (Table I) . MS-HRM analysis was performed on the Applied Biosystems w StepOnePlus TM Real-Time PCR System using the following conditions: 1 cycle of 958C for 10 min, 40 cycles of 958C for 15 s, primer-specific annealing temperature for 1 min and followed by an HRM step of 958C for 10 s, 608C for 1 min and continuous acquisition to 958C for 15 s with a ramp rate of 0.3%. PCR was performed in a final volume of 20 ml, containing 10 ml of master mix (MeltDoctor TM MS-HRM Master Mix, Applied Biosystems, Inc., Life Technologies Corporation), 250 nM of each primer, 1.5 mM MgCl 2 and 1 ml (almost 30 ng) of bisulfite modified DNA template. The data obtained via the Stepone plus software were then analyzed with the Applied Biosystems w MS-HRM software (v.3.0.1.). Standard curves were included in each assay and to deduce the methylation percentage values for each sample according to the method of Migheli et al. (2013) by imputing the average aligned fluorescence value of each sample in the Polyfit interpolation curve (MatLab program-The MathWorks, Inc., USA) obtained for methylation standards ranging from 0 to 100% used in the particular MS-HRM assay. Each aligned fluorescence percentage value for a single methylation standard was calculated as an average of fluorescence units of the temperatures relative to the melting status in a specific temperature range (from 72.1 to 78.98C for c-myc and from 75.9 to 82.98C for hTERT).
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation assay (ChIP) assay was used to evaluate the presence of a particular histone modification within the promoter region of c-myc and hTERT. Histones were cross-linked to DNA by incubating placental villi samples (25 mg) from normal gestational groups, PE and hydatidiform mole (4 samples in each group) in 1.5% formaldehyde on a rocker for 10 min, and cross-linking was stopped by adding glycine to a final concentration of 125 mM. Ice-cold PBS was used to wash placental villi followed by disaggregation using the Dounce homogenizer in 1 ml lysis buffer (NaCl 150 mM, Tris HCl (pH 7.5), 25 mM, EDTA 5 mM, Trition X 100 1%, SDS 0.1%, Sodium deoxycholate 0.5%, PMSF 1 mM, Sodium butyrate 10 mM, Protease inhibitor cocktail [PIC] 1X) to obtain a single-cell suspension. The suspension was centrifuged and the cell pellet was washed sequentially in wash buffer 1 (Triton X 2100 0.25%, EDTA 10 mM, EGTA 0.5 mM, HEPES (pH 7.5) 10 mM, PMSF 1 mM, Sodium butyrate 10 mM, PIC 1×) and wash buffer 2 (NaCl 0.2M, EDTA 1M, EGTA 0.5 mM, HEPES (pH 7.5), 10 mM, PMSF 1 mM, Sodium butyrate 10 mM, PIC 1×) followed by resuspension in lysis buffer for sonication using Bioruptor XL (Diagenode, Belgium) at 20 pulses of 10 s each. The sonicated sample was centrifuged at 13 000 g for 10 min at 48C and then incubated with protein A/G-polyacrylamide beads alone (UltraLink w Resin, Thermo Scientific, Rockford, IL, USA) for 4 h at 48C on a rocker to preclear the lysate. Supernatant was then divided into three aliquots: the first aliquot was used for input DNA (10% of total supernatant); the other two aliquots were used for immunoprecipitation with anti-trimethyl H3-K9 (rabbit polyclonal) and H3-K27 (mouse monoclonal) antibody (45% of total supernatant, from Abcam, Cambridge, England, UK, cat. no. ab8898 and ab6002, respectively) and normal rabbit immunoglobulin G (IgG) (45% of total supernatant, from Santa Cruz Biotechnology, Santa Cruz, CA, USA, cat. no. sc-2027) for isotype control, at 48C overnight. To collect immunoprecipitated complexes, the suspension was incubated with protein A/G-polyacrylamide beads for 4 h at 48C. Beads were harvested and washed with RIPA and TE buffers (10 mM Tris 1 mM EDTA, pH 8.0). The cross-links were reversed by heating the samples with 4 M NaCl at 658C for 4 h, followed by treatment with RNase (100 mg/ml final concentration) for 30 min at 378C and then proteinase K (100 mg/ml final concentration) overnight (all ChIP reagents were purchased from Sigma Chemical Co.). DNA was extracted by the phenol -chloroform method, ethanol precipitated and resuspended in deionized water. Quantitative real-time PCR was carried out to estimate the amount of immunoprecipitated DNA using the primers designed by Applied Biosystems Primer Express Software v3.0.1 for the promoter region of c-myc and hTERT (Table I ). The PCR program was set as: 1 cycle of 958C for 10 min, 40 cycles of 958C for 15 s, primer-specific annealing temperature for 1 min and followed by a melt curve of 958C for 10 s, 608C for 1 min and 958C for 15 s. PCR was performed in a final volume of 20 ml, containing 10 ml of SYBR Green master mix (Applied Biosystems, Inc., Life Technologies Corporation), 500/150 nM primers for c-myc and hTERT, respectively, 1.5 mM MgCl 2 and 1 ml of immunoprecipitated DNA. The assays were performed in triplicate and the levels of histone tail modifications were calculated by the fold enrichment method relative to the non-specific antibody and normalized to the input DNA.
Statistical analysis
All statistical analyses were performed using the SPSS software for Windows version 16.0 and GraphPad Prism software version 5.00.288. Between-group comparisons were made using one-way ANOVA; if found to be significant, 
Results
Quantification of mRNA expression of c-myc and hTERT
Quantification of c-myc mRNA expression revealed a decrease in mRNA levels with advancing gestation, a significant decrease being observed in the normal third-trimester versus the first (3.5-fold) and second (2.5-fold) trimester (P , 0.001) groups. In both disorder groups, c-myc expression was dysregulated, with a 4.1-fold (P , 0.001) decrease in PE versus normal third-trimester placenta and 1.4 (P , 0.05) and 2-fold (P , 0.001) higher in molar placenta when compared with firstand second-trimester normal placentas, respectively. Progression to choriocarcinoma was found to be associated with a further rise in c-myc mRNA levels as depicted by 1.9 (P , 0.05) and 2.8 (P , 0.001) fold increased c-myc expression in choriocarcinomic cell line JEG-3, when compared with molar placenta and normal first-trimester placenta, respectively (Fig. 1a) . The c-myc mRNA expression level in maternal leukocytes (Fig. 1b ) increased by 3.1 (P , 0.01) and 6.2 (P , 0.001) fold in the secondand third-trimester, respectively, when compared with first-trimester maternal leukocytes. The c-myc mRNA levels were also raised in molar maternal leukocytes by 2.7-fold (P , 0.01) versus the normal firsttrimester group. A comparison of c-myc mRNA levels between placental villi and their corresponding maternal leukocytes (Fig. 1c) showed higher relative expression in the first-trimester placenta (12.8-fold, P , 0.001), second-trimester placenta (2.9-fold, P , 0.05) and molar placenta (6.8-fold, P , 0.001). In normal third-trimester placenta and PE there was a non-significant difference in c-myc expression between placental villi and maternal leukocytes. Analysis of the placental-derived cell lines showed a significantly raised level (P , 0.001) of c-myc mRNA in HTR-8/SVneo cells when compared with JEG-3 cells (4.4-fold) and normal first-trimester placenta (12.7-fold) (Fig. 1d) .
mRNA expression level of hTERT in placental villi was 5.4-fold (P , 0.001) higher in pre-eclamptic villi compared with its respective control. Decreasing levels of hTERT mRNA were observed with increasing gestation age, as shown by the 4.9-fold (P , 0.001) decrease in thirdtrimester placenta when compared with first-trimester. Progression to choriocarcinoma may be associated with raised hTERT mRNA levels, as shown by 6.5-to 8.9-fold higher hTERT transcript levels in JEG-3 cells versus normal first-and second-trimester and molar placentas (Fig. 2a) . The overall expression of hTERT is very low in all normal gestational villi groups in reference to HTR-8/SVneo cells, with a difference in DCt values ranging from 8 to 10 between first-trimester and thirdtrimester villi versus HTR/8SVneo cells, respectively.
In maternal leukocytes advanced gestation age was associated with decreased hTERT mRNA levels, which decreased by around 2-fold in the second and third trimester groups (P , 0.001). Further, the molar group showed a significant increase by 1.98-fold (P , 0.01) in hTERT mRNA levels compared with second-trimester maternal leukocytes (Fig. 2b) . hTERT mRNA expression was significantly lower (P , 0.001) in all maternal leukocyte groups compared with their respective placental groups (Fig. 2c) . This difference was least in the third-trimester group among the normal groups. However, pre-eclamptic and molar placental villi had a 17-fold and 6.2-fold higher level of hTERT mRNA, respectively, than their respective maternal leukocytes. HTR-8/SVneo cells showed a higher expression of hTERT mRNA (33-fold) relative to JEG-3 cells and 217-fold higher than that of the normal first-trimester placenta (P , 0.001) (Fig. 2d) .
Methylation status of CpG islands in the promoter region of c-myc and hTERT
On the basis of the methylation percentage as revealed by MS-HRM, we defined the placental villi groups as hypomethylated and hypermethylated. The promoter region methylation pattern for c-myc is shown in Fig. 3a-d . With the exception of pre-eclamptic villi, all groups showed hypomethylation at the c-myc promoter (Fig. 4a) . In pre-eclamptic villi there was 71.5% (P , 0.001) increase in c-myc promoter methylation versus normal third-trimester placenta. The Pearson correlation analysis of the correlation between the methylation percentage for the c-myc promoter in pre-eclamptic villi and its corresponding mRNA expression showed a high negative correlation coefficient value of 20.9, P , 0.01. Although first-trimester placental villi showed statistically significant methylation for c-myc promoter compared with other placental villi groups (except pre-eclamptic villi), methylation of the c-myc promoter was not observed to correlate with c-myc mRNA expression in these placental villi groups.
The c-myc promoter region within maternal leukocyte groups was also hypomethylated, with a similar comparatively higher methylation in the first-trimester compared with the third-trimester (P , 0.01) and molar group (P , 0.05); however, no other significant differences were observed (Fig. 4b) . Comparing the percentage of methylation between placental villi samples and their corresponding maternal leukocytes revealed a highly significant difference only in the preeclamtic group, with 76.6% higher methylation in pre-eclamptic villi (P , 0.001) versus its maternal group (Fig. 4c) . In placental cell lines and isolated cytotrophoblasts (Fig. 4d) , the c-myc promoter was significantly less methylated (by 19.5%) in JEG-3 cells (P , 0.05), 24% in HTR-8/SVneo cells (P , 0.01) and 16.2% (P , 0.05) in cytotrophoblasts when compared with the normal first-trimester placenta. The promoter region methylation analysis of hTERT revealed a completely unmethylated promoter in all categories (Fig. 5a-c) .
Histone modifications within the promoter regions of c-myc and hTERT
Histone modification was quantified as the relative amount of each histone modification in different placental villi groups above the background. We targeted two main silencing modifications, i.e. trimethylation of H3K9 and H3K27. In case of c-myc, H3K9me3 was significantly raised 6.7-fold (P , 0.05) in the third-trimester placenta when compared with the 4.4-fold increase above the background in the firsttrimester placenta, while molar placenta showed a lower level of H3K9me3 when compared with normal first-and second-trimester placenta (Fig. 6a) . The H3K27me3 pattern in c-myc was raised in PE 2.4-fold (P , 0.01) relative to normal third-trimester placenta, while being lower by 2.6-fold (P , 0.05) in molar placenta versus normal second-trimester placenta (Fig. 6b) ; however, it was almost equal in all normal gestational groups at around 3.8-fold. Pearson's correlation analysis (used to study the independent relation of each epigenetic modification and mRNA expression of c-myc) revealed a significantly high correlation between different epigenetic modifications and mRNA expression of c-myc. The Pearson's correlation coefficient value between its different parameters, being 20.99, P , 0.001 and 20.82, P , 0.05 for mRNA expression and H3K9me3 and H3K27me3 levels, respectively, thus suggesting a strong regulation of c-myc mRNA expression by epigenetic modifications. Further, c-myc promoter region DNA methylation was also found to be strongly correlated with H3K27me3 levels (0.89, P , 0.05). This was further validated by a significantly higher regression coefficient (r 2 ¼ 1, P , 0.01), showing the combined effect of various epigenetic modifications on the mRNA expression of c-myc (Table II) .
As revealed by ChIP analysis, the hTERT promoter region showed significant difference in the level of H3K9me3 only in PE placenta, being 2.2-fold lower (P , 0.01) than in the normal third-trimester placenta, while no significant difference was observed in the other categories (Fig. 7a) . Levels of H3K27me3 in the hTERT promoter decreased significantly by 1.8-fold (P , 0.05) in PE placenta when compared with normal third-trimester placenta. The third-trimester placenta exhibited a 1.9-fold (P , 0.05) higher level of H3K27me3 when compared with the first-trimester placenta. However, H3K27me3 was significantly lower by 2.9-fold (P , 0.001) in molar placenta when compared with the second-trimester placenta (Fig. 7b) . Correlation analysis between its mRNA expression and various histone modifications revealed a strong inverse correlation with H3K9me3 (r ¼ 20.77) and H3K27me3 (r ¼ 20.78). On multiple regression analysis, a stronger impact was observed on mRNA expression of hTERT, as shown by significantly higher r 2 values of 0.99, P , 0.05 (Table II) . . The data were compared using one-way analysis of variance (ANOVA), followed by Fisher's post hoc test between ≥3 variables, while Student's t-test was used for 2 variables and are expressed as the mean fold change + SEM, for 30 patients in each group. Trim ¼ trimester.
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Correlation between mRNA expression of c-myc and hTERT
Pearson's correlation analysis revealed a strong positive correlation between the expression profiles of c-myc and hTERT (r ¼ 0.94, P , 0.02) between normal placental villi groups and the choriocarcinoma cell line JEG-3 (with the exception of pre-eclamptic villi). This was further validated by analyzing the correlation of c-myc and hTERT mRNA expression within molar placental villi samples and JEG-3 cells, showing a strong positive Pearson correlation coefficient of 0.88, P , 0.01 and 0.99, P , 0.02, respectively. These data strongly suggest the coordination of c-myc and hTERT mRNA expression in the development of molar pregnancy and further its progression to choriocarcinoma.
Fetal epigenetic markers in maternal plasma
To validate the methylated promoter region of a particular gene as a potential fetal epigenetic marker, the placental epigenetic pattern of that gene should be found in the maternal plasma. We studied the promoter region of c-myc in maternal plasma in the pre-eclamptic group based on the observation of a significant difference of 76.6% in promoter region methylation between pre-eclamptic placental villi and the corresponding maternal blood leukocytes. Our analysis ( Fig. 8a and b ) revealed an average of 53 + 16% methylation for the c-myc promoter in maternal plasma samples, which was significantly higher (P , 0.001) than that in maternal leukocytes. This hypermethylated pattern of the c-myc promoter in maternal plasma mimics the methylation pattern of c-myc in preeclamptic placenta, thus indicating the presence of hypermethylated fetal c-myc in maternal plasma and supporting the use of c-myc as an epigenetic marker in PE.
Discussion
Development of the placenta is a complex molecular event that involves proliferation, migration and invasion of placental trophoblasts into the myometrium of the uterus and its vasculature in order to nourish the developing fetus, in a way that is similar to that in most malignant tumors (Soundararajan and Rao, 2004; Ferretti et al., 2007) . Several . The data were compared using one-way ANOVA, followed by Fisher's post hoc test between ≥3 variables, while Student's t-test was used for 2 variables and are expressed as the mean fold change + SEM, for 30 patients in each group.
oncogenes, such as c-fos, c-jun and c-myc, are similarly expressed by both normal trophoblasts and cancer cells (Bamberger et al., 2004) and are known to play an important role in the proliferative and invasive nature of the placenta. Human placenta also shows high telomerase activity, as in most progressive cancers (Soundararajan and Rao, 2004) . In this study we analyzed the role of epigenetic mechanisms in the regulation of the differential expression of c-myc and hTERT in normal villous tissue from each trimester and in molar and pre-eclamptic villi, based on recent studies highlighting the possibility of common epigenetic modifications in trophoblasts and cancer cells which facilitate their proliferative, migratory and invasive properties (Ferretti et al., 2007; Serman et al., 2007) . The expression data for c-myc and hTERT in our study, suggesting the highest expression in the first trimester relative to other normal gestational groups and being abnormally high in a molar pregnancy and choriocarcinoma cell line, are consistent with the previously reported studies (Pfeifer-Ohlsson et al., 1984; Fulop et al., 1998; Chen et al., 2002) . These observations suggest a role for c-myc and hTERT in the proliferation and invasive potential of placental trophoblasts in these cases, supported by the fact that gametes, stem and tumor cells show unlimited replicative potential due to activation of telomerase that compensates for telomere shortening (Kim et al., 1994 ). The observed significantly lower level of hTERT expression in normal early trimester placenta with limited proliferative and invasive potential relative to choriocarcinoma (showing uncontrolled invasive and proliferative potential) also supports the role of higher hTERT expression, and thus maintenance of telomeric length, for indefinite proliferation and invasion. The role of c-myc and hTERT in promoting trophoblast invasiveness and proliferation is further supported by the decreasing expression of these genes in the order of decreasing invasive and proliferative potential: in HTR-8/SVneo cells followed by JEG-3 cells and the least invasive first-trimester villi (Suman and Gupta, 2012) .
The observed high positive Pearson's correlation value between c-myc and hTERT expression in normal placental villi groups and GTD groups (molar villi and JEG-3 cells) in this study strongly emphasizes the role of c-myc in enhancing the expression of hTERT, which is one of its downstream target genes (Horikawa et al., 1999) , and further supports the observation that abnormally higher c-myc expression might therefore be a Epigenetic regulation of c-myc and hTERT in human placenta factor responsible for uncontrolled up-regulated expression of hTERT in GTD. Further, hydatidiform moles are genetically abnormal (complete hydatidiform moles being diploid and androgenic in origin (Hoffner and Surti, 2012) ), while partial hydatidiform moles are triploid (Lawler et al., 1979) . Thus, based on our observations and genetic abnormalities linked to the hydatidiform mole, we can suggest that higher c-myc expression inducing abnormal expression of hTERT might be a contributing factor for the uncontrolled proliferation and invasion observed in the hydatidiform mole.
To delineate the epigenetic mechanisms regulating the expression of c-myc and hTERT under these conditions, we studied the role of DNA methylation and post-translational histone modifications, which are the two main aspects of epigenetic regulation working in concert for regulating gene expression (D'Alessio and Szyf, 2006; Klose and Bird, 2006) . Maintenance of these epigenetic marks is necessary for the normal physiological behavior of the cells, while in case of many tumors there is an aberrant change in these epigenetic marks, resulting in an abnormal transcriptional profile (Costello et al., 2000; Fraga et al., 2005; Song et al., 2005; Bernstein et al., 2007; Esteller, 2007) . In view of the close resemblance between placental development and the process of tumorigenesis, some tumor-associated methylation and histone modifications have been observed in the placenta (Dokras et al., 2006; Novakovic et al., 2008; Wong et al., 2008) . Our analysis of the role of DNA methylation in regulation of c-myc and hTERT differential expression in placenta villi samples and their corresponding maternal blood samples revealed either unmethylated or hypomethylated promoter regions, thus ruling out DNA methylation of these genes as a regulatory mechanism for their differential expression. However, in case of pre-eclamptic villi, hypermethylation of the c-myc promoter region was associated with repressed c-myc expression. Such abnormal DNA methylation regulating the enzymes modulating vitamin D homeostasis at the fetomaternal interface has also been reported for Vitamin D deficiency associated Trim. The data were compared using the Student's t-test.
Epigenetic regulation of c-myc and hTERT in human placenta with PE (Bodnar et al., 2007; Novakovic et al., 2009) . Lower expression of c-myc in PE further supports the abnormal cytotrophoblast differentiation and invasion observed in PE (Brosens et al., 1972; Uzan et al., 2011) . Although methylation was observed in the c-myc promoter region in first-trimester villi, it could not be correlated with the mRNA expression of first-trimester villi, therefore emphasizing the role of other epigenetic mechanisms in the regulation of differential expression. Like DNA methylation, the level of histone modification is known to be lower in the trophoblast lineage compared with the embryonic lineage (Torres-Padilla et al., 2007) but the histone modifications in normal extraembryonic development is indispensable, supported by the failure of invasive trophoblast giant cell differentiation (Wang et al., 2002) and amnion and chorion formation (Pasini et al., 2004) due to mutations in PcG repressive complex (PRC) 2 mediating H3K27 methylation (Hemberger, 2007) . Based on the importance of histone modifications in placental development, we analyzed H3K9me3 and H3K27me3 in the transcriptional regulation of c-myc and hTERT. These modifications are known to play an important role in transcriptional silencing, being the hallmarks of inactive DNA (Lachner and Jenuwein, 2002; Kondo et al., 2008) .
Histone modifications have been reported to regulate the placentalspecific expression of five genes of the human growth hormone cluster with different roles for HAT and HMT co-activator complexes (Alsat et al., 1998; Kimura et al., 2004) , thus highlighting the special importance of histone modifications in placental development. In support of the role of histone modifications in placental gene regulation, we were able to identify increased levels of H3K9me3 and H3K27me3 in normal placental villi at the c-myc and hTERT promoter, respectively, with advancing gestation resulting in a decrease in the expression of these genes in human placenta. Methylation of H3K9 has also been reported to be associated with a lack of hTERT expression in telomerase-negative cell lines (Atkinson et al., 2005) . The five placental villi groups included were normal first, second and third trimester, pre-eclampsia and molar villi. r ¼ Pearson's coefficient, r 2 ¼ regression determination coefficient, UD ¼ undetermined due to the unmethylated gene promoter. In case of regression analysis, the equation for prediction for each gene was 'mRNA expression ¼ b1H3K9me3 + b2H3K27me3 + b3DNA methylation + a', where b1, b2, b3 are regression coefficients and a is the intercept of the test. *P , 0.05, **P , 0.01 and ***P , 0.001.
Figure 7
ChIP for hTERT promoter region in different placental villi groups. Relative fold enrichment in (a) H3K9me3 and (b) H3K27me3, relative to negative control (normal rabbit IgG) and normalized with input DNA. The values are expressed as the mean fold change + SEM; n ¼ 4 per group. *P , 0.05 with respect to 1st Trim, ### P , 0.001 with respect to 2nd Trim and E P , 0.05, E E P , 0.01 with respect to 3rd Trim. The data were compared using the Student's t-test.
Further, our study highlighted the role of trimethylation of H3 lysine residues in the development of PE and molar pregnancy. A lower level of H3K27me3 at the promoter region of c-myc as well as hTERT was associated with molar pregnancy. Lower H3K9 methylation at the c-myc and hTERT gene promoter is reported to be involved in their activation in leukemia and hepatocellular carcinoma, respectively (Foltankova et al., 2012; Zhang et al., 2014) . Lower methylation of H3K9 or H3K27 at the hTERT promoter is also supported by the reported low level of repressive histone marks and higher level of activating acetylation histone marks on c-myc-target genes (Guccione et al., 2006; Martinato et al., 2008) .
The contrasting mRNA expression levels of c-myc and hTERT in preeclamptic villi highlight some possible factor that induces opposite effects on c-myc and hTERT expression in these cases. In our study we have observed contrasting histone modifications as one such possible factor, with higher H3K27me3 levels at the c-myc promoter and lower trimethylated H3 lysine residues at the hTERT promoter. Thus, in case of PE, both promoter region DNA methylation and higher H3K27me3 levels at the c-myc promoter might be the combined epigenetic factors regulating the lower expression of c-myc in preeclamptic villous tissue. These results thus emphasize the possible role of epigenetic dysregulation at the c-myc promoter in the development of PE, but further studies are required to confirm these findings. Furthermore, PE (Caniggia et al., 1999 ) is reported to be associated with hypoxia-like conditions, resulting in aberrant gene expression. Hypoxia is associated with the expression of hypoxia-inducible factor 1a (HIF-1a) (Caniggia et al., 1999) , which is involved in enhancing hTERT expression (Zhang et al., 2003) and inducing the expression of hTERT in a choriocarcinoma cell line (Nishi et al., 2004) . Moreover, hypoxia and HIF have also been reported to decrease c-myc expression in human lung carcinoma and in renal cell carcinoma (Zhang et al., 2007) . Furthermore, in lung carcinoma hypoxia associated with lower global acetylated histone4 was mediated by lower c-myc expression (Li and Costa, 2009 ). These studies thus support the higher expression of hTERT reported previously (Geifman-Holtzman et al., 2010) and lower expression of c-myc in PE as observed in the present study. Although the inverse relation between expression of c-myc and hTERT in pre-eclamptic placental villi seems to be associated with hypoxia as well as the opposite epigenetic modifications for these genes in this particular group, in case of early trimester villi where a physiologically low oxygen environment prevails, the higher expression of c-myc, as observed in this study and as reported previously (PfeiferOhlsson et al., 1984; Fulop et al., 1998) , seems to be regulated by histone modifications. Moreover, there is co-localization and higher expression of the platelet-derived growth factor early in pregnancy, which is known to stimulate the expression of c-myc (Goustin et al., 1985; Osterlund et al., 1996) . C-myc is part of the postreceptor intracellular signaling pathway for the stimulation of cell proliferation by growth factors. Furthermore, the higher expression of these genes in early trimester villi is also consistent with the higher invasive potential of first-trimester trophoblasts (Goustin et al., 1985) .
Analysis of hTERT and c-myc expression in placental tissue in reference to maternal blood revealed significantly higher expression in placental villi, which supports the known higher proliferative and malignant phenotype of placental villi. This observation is substantiated by a previous study where longer telomeres are observed in placenta tissue than in cord blood from the same donor (Allsopp et al., 2007) . ′ CpG Methylation among different pre-eclamptic placental villi samples (PE villi), their corresponding maternal blood leukocytes (PE blood) and plasma samples collected previous to the obstetric procedure from pre-eclamptic women (PE plasma) and women with normal pregnancy in the 3rd trimester (3rd Trim plasma). The data were compared using the Student's t-test and are expressed as the mean percentage of methylation + SEM. ***P , 0.001 with respect to the respective maternal blood leukocytes, for 30 patients in each group.
Based on these findings, we suggest a role for epigenetic mechanisms in the regulation of c-myc and hTERT differential expression, with higher expression in the first trimester, promoting its proliferative capacity and thus its higher cancer-like phenotype. We also suggest that further dysregulation of this epigenetic modification is a potential factor in the development of PE and molar pregnancy, as supported by the high regression coefficient observed in our study. Future studies establishing the role of histone modifications in placental villi and maternal blood may further elucidate the role of epigenetic mechanisms in placental development.
The presence of cell-free fetal DNA in maternal plasma holds promise for the development of non-invasive prenatal genetic diagnostics since it is a better source of fetal DNA than fetal cells in maternal plasma (which are low in number) and is also unique to the current pregnancy, as it is cleared from maternal plasma within 24 h after delivery. Cell-free fetal DNA in maternal plasma has recently been analyzed to search for fetal DNA epigenetic markers, such as RASSF1A and maspin (Chim et al., 2005; Chan et al., 2006) , with the potential of being used in physiological pregnancies as well as pathological pregnancies; however, no specific epigenetic marker for pathological pregnancies has been identified to date. In this regard, we studied the promoter region of c-myc in pre-eclamptic maternal plasma because of its considerably higher level of methylation in pre-eclamptic villi than in maternal DNA. Placenta is the most likely organ for releasing fetal nucleic acids into maternal plasma (Alberry et al., 2007) , while maternal blood cells are the main source of background maternal DNA (Lui et al., 2002) . The methylation pattern observed in circulating fetal DNA should be the same as that of the placental villi. Based on our finding of a significantly higher methylation level of c-myc promoter in maternal plasma, mimicking the methylation status of pre-eclamptic villi, we suggest c-myc as a possible specific fetal epigenetic marker for preeclamptic pregnancy. However, in order to be of clinical value, our findings need to be validated and also repeated in early pregnancy. An earlier study used the difference in median concentration of hypermethylated RASSF1A to differentiate pre-eclamptic pregnancies from normal pregnancies (Zhao et al., 2010) . This approach makes use of RASSF1A as an epigenetic marker of PE and is dependent on the concentration of fetal DNA in maternal plasma, which shows high between-subject variation, whereas in our study we used the exact percentage of methylation of c-myc in maternal plasma to differentiate pre-eclamptic pregnancies from normal pregnancies. Furthermore, c-myc was observed to be hypermethylated only in PE, making it a specific marker for PE.
In conclusion, this is a preliminary study reporting, for the first time, a hypermethylated c-myc promoter in maternal plasma and requires further validation in a larger population and in early pregnancy in order to establish the use of c-myc as an early diagnostic marker for preeclamptic pregnancies in the future.
